This collection of content will continually bring you the latest news, research and FDA approvals relating to leukemia and lymphoma.
New! CLL Clinical Trials
Paolo Strati, MD, a recipient of ASCO’s Young Investigator Award, describes two CLL clinical trials under way.
New! EU Approval of Venetoclax Plus Rituximab for the Treatment of CLL
The European Commission has approved the type-II variation application for venetoclax in combination with rituximab for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) who have received at least one prior therapy.
Paolo Strati, MD, from The University of Texas MD Anderson Cancer Center, shares what he predicts will be the next big achievements or milestones in CLL.
New! Promising Results of 177Lu-Satetraxetan-Lilotomab in R/R Indolent non-Hodgkin Lymphoma
Updated results from the LYMRIT 37-01 phase I/II clinical study of 177Lu-satetraxetan-lilotomab in patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL) has been published ahead of its presentation in a poster at the American Society of Hematology Annual Meeting & Exposition being held Dec. 1-4 in San Diego.
New! Evaluating 5F9 in Combination With Rituximab for Patients With Relapsed/Refractory NHL
Proof-of-concept data from the phase 1b portion of a phase 1b/2 clinical trial evaluating 5F9 in combination with rituximab in patients with relapsed/refractory non-Hodgkin lymphoma (r/r NHL) was recently published in the New England Journal of Medicine (NEJM).